Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

622 results about "Protecting group" patented technology

A protecting group or protective group is introduced into a molecule by chemical modification of a functional group to obtain chemoselectivity in a subsequent chemical reaction. It plays an important role in multistep organic synthesis.

Preparation method of nerofloxacin chiral piperidylamine intermediate

PendingCN121108037AOrganic chemistryPlatinum oxideCarboxylic acid
The invention relates to a method for preparing a nerofloxacin chiral piperidylamine intermediate, which comprises the following steps of: carrying out condensation reaction on 5-hydroxy nicotinic acid which is simple and easy to obtain and is used as a raw material and different alcohols, screening through a series of asymmetric catalytic hydrogenation conditions to obtain optimal reaction conditions, and under the conditions, carrying out reaction on various 3, 3 '-dihydroxy nicotinic acid and 3, 3'-dihydroxy nicotinic acid to obtain the nerofloxacin chiral piperidylamine intermediate. The 2, 5-disubstituted pyridine quaternary ammonium salt is reduced into a tetrahydropyridine product, and the C5 site enantioselectivity of the product is excellent. The preparation method comprises the following steps: selecting methyl (R)-1-benzyl-5-hydroxy-1, 4, 5, 6-tetrahydropyridine-3-carboxylic acid methyl ester as a substrate, completely hydrogenating by using platinum dioxide hydrogen, and then carrying out methyl ester reduction, dehydroxylation, Mitsunobu reaction and protecting group removal to obtain a key chiral intermediate for industrial synthesis of a quinolone antibacterial drug nemonofloxacin with high enantioselectivity and high yield.
Owner:SICHUAN UNIV

Reagents and processes for preparing oligonucleotides

The present disclosure describes novel reagents and processes for preparing oligonucleotides, which have two or more nucleotides. In one embodiment, the reagent is represented by Formula I. wherein: W is O or NH; R1 is -H or a solid support; R2 is a silyl hydroxyl protecting group or an alloc protecting group, R3 is a nucleoside or a group represented by (II) wherein (III) represents the point of attachment for R3.
Owner:BIOGEN MA INC

Preparation method of alplsutentan and alplsutentan intermediate

The invention discloses a preparation method of alplsutentan and an alplsutentan intermediate, alplsutentan is obtained by taking a compound SM1 as a raw material through a one-step method or a multi-step method, and the multi-step method comprises the following steps: reacting the compound SM1 with a compound SM2 to obtain an intermediate I; reacting the intermediate I with 2-[(5-bromo-2-pyrimidinyl) oxy] ethanol to obtain an intermediate II, or reacting the intermediate I with ethylene glycol to obtain an intermediate I-b, and then reacting with 5-bromo-2-chloropyrimidine or 5-fluoro-2-chloropyrimidine to obtain the intermediate II; and finally, removing a protecting group from the intermediate II to obtain alpoxivan. The one-step method comprises the following steps: when X in a compound SM1 is a fluorine atom, the compound SM1 is 5-(4-bromophenyl)-4, 6-difluoropyrimidine, and the compound SM1 reacts with sulfonamide and 2-[(5-bromo-2-pyrimidinyl) oxy] ethanol to directly obtain alpoxivan. The synthesis route is short, and the reaction conditions are mild.
Owner:NANJING DOYLE PHARM RES INST CO LTD

Method for preparing zavegepant intermediate and derivative thereof

The present invention relates to the field of drug synthesis, and specifically relates to a method for preparing a Zavegepant intermediate and a derivative thereof. Specifically, the method comprises reacting a compound of formula II with a compound of formula III to obtain a compound of formula I, reacting the compound of formula I with isoamyl nitrite to obtain compound V, and removing a protecting group from the compound of formula V to obtain a compound of formula VI or a salt thereof. On the basis of the preparation method provided by the present invention, the raw materials are readily available, the production cost is relatively low, there are fewer synthesis steps, and the operation is simpler and more convenient.
Owner:SHANGHAI SYNCORES TECH INC +1

A pag key type photosensitive photoresist resin and a preparation method thereof

The application discloses a PAG bonding type photosensitive photoresist resin and a preparation method and application thereof. The photoresist resin is as follows: formula. The PAG bonding type resin is prepared through the following reaction process: 1) performing a RAFT polymerization reaction on p-acetoxystyrene, p-styrene sulfonamide trifluoromethyl potassium salt and a RAFT chain transfer agent under the action of an initiator to obtain an intermediate I, 2) performing a hydrolysis reaction on the intermediate I to obtain an intermediate II, 3) performing a protection group introduction reaction on the intermediate II and di-tert-butyl dicarbonate to obtain an intermediate III; and 4) performing an ion exchange reaction on the intermediate III and triphenylsulfonium bromide. The application realizes the bonding of the PAG into the resin skeleton, and improves the problems of poor compatibility between the PAG and the resin, phase separation, uneven distribution of the PAG and the like. Therefore, the photoresist prepared from the resin has the photo-generated acid bound by the polymer main chain and limited diffusion, the resolution is improved, and the photoetching effect is excellent.
Owner:HANGZHOU XIANYAN TECH CO LTD +1

Preparation method of protecting group cefdil side chain acid

The invention discloses a preparation method of protecting group cefdil side chain acid. The preparation method comprises the following reaction steps: step 1, performing oximation reaction on a compound IV to obtain a compound V; 2, cyclizing the compound V and thiourea to obtain a compound VI; 3, condensing the compound VI and tert-butyl alpha-bromoisobutyrate to obtain a compound VII; 4, the compound VII passes through a protective group to obtain a compound VIII; and 5, hydrolyzing the compound VIII to obtain the product protecting group cefdil side chain acid. The raw materials used in the method are simple and easy to obtain, expensive reagents and customized raw and auxiliary materials are not used, the process operation is simple, a major dangerous process is not involved, and the method has industrial advantages.
Owner:HANGZHOU GUORUI BIO TECH CO LTD

Method for producing protected glycoside derivative

Provided is a method for producing a protected glycoside derivative, including reacting a sugar in which all hydroxyl groups of the sugar are protected by protective groups and protective groups of a hydroxyl group at a 1-position and a hydroxyl group at a 2-position are acyl groups, with a phenolic compound in the presence of at least one catalyst selected from the group consisting of trifluoromethanesulfonic acid and copper (II) trifluoromethanesulfonate, in which the phenolic compound is bonded to an anomeric position of the sugar and other hydroxyl groups of the sugar are protected.
Owner:RESONAC CORP

Intermediate of gepodamycin, preparation method of intermediate of gepodamycin and preparation method of gepodamycin

The invention relates to the technical field of compound synthesis, in particular to an intermediate of gepodalin, a preparation method of the intermediate and a preparation method of gepodalin. The intermediate of gepodamycin is selected from any one of compounds shown in the following structural formula, and in the formula, X represents halogen, and R1 represents a hydroxyl protecting group; r2 represents an amino protecting group, and R3 represents a C1-C10 alkyl group. The intermediate can be synthesized to obtain the core intermediate of gepodamycin through a series of new synthesis steps, and the yield, the purity and the post-treatment difficulty of the core intermediate can be improved, so that the production cost of gepodamycin is greatly reduced.
Owner:北京海美源医药科技有限公司

Synthesis process of oligonucleotide with sulfo-PMO structure

The invention discloses an oligonucleotide synthesis process of a sulfo-PMO structure. In the oligonucleotide synthesis process of the sulfo-PMO structure, the molecular structural formula of sulfo-PMO is shown in the specification. According to the invention, the molecular structure of thio-PMO is specifically limited, and the synthesis of nucleotide phosphate amide and (thio) phosphoric acid amide in the solid-phase synthesis oligonucleotide is carried out along the direction from 5'to 3 ', that is, in each cycle period, the O5'or O6' position of the nucleotide phosphate amide and (thio) phosphoric acid amide monomer is firstly subjected to coupling reaction, and then the protecting group is removed at the O3 'or N3' position, so that the oligonucleotide phosphate amide and (thio) phosphoric acid amide are obtained. And releasing active hydroxyl or amino / amido to enter the next cycle. The protecting group adopted by the sulfo-PMO molecule is consistent with the protecting groups of other nucleotides, so that the conversion rate of each step of coupling reaction can be conveniently detected on line.
Owner:SUZHOU SHENGNUOWEI BIOTECH CO LTD

A method of preparing maraviroc

The application provides a novel preparation method of maraviroc, which forms a stable intermediate by protecting phenolic hydroxyl with n-pentyl, so that the condensation with (R)-(+)-tetrahydrofuran-2-formyl chloride has a high yield, and the by-products generated by removing the protecting group in the reaction process are reduced; the use of the controlled reagent 1-propyl phosphonic anhydride in the condensation of (R)-(+)-tetrahydrofuran-2-formic acid in the original process is eliminated. In the subsequent docking with the C fragment, by adjusting the polarity of the solvent, the product is easily precipitated, the conversion rate is improved, and the product is easy to separate and purify, so that the problem of low conversion rate of the protecting group reported in the literature is solved. The improved method has the advantages of simple reaction and operation, easy impurity removal, and a reaction yield increased by about 10% compared with the previous method, and is an industrialized amplification implementation feasible process.
Owner:SHANGHAI DESANO BIO PHARM CO LTD +3

Chemical-enzymatic coupling synthesis method of oseltamivir phosphate

The invention discloses a chemical-enzymatic coupling synthesis method of oseltamivir phosphate, which comprises the following steps: by taking monasic acid OS-01 as a substrate, sequentially carrying out S1 esterification, S2 ketalation, S3 selective ring opening, S4 TEMPO oxidation, S5 primary transaminase reaction, S6 acetylation, S7 secondary transaminase reaction and S8 phosphorylation reaction to obtain the final product oseltamivir phosphate OS-09. According to the method, the step of sodium azide required by a traditional route is avoided, the production safety and the industrialization possibility are enhanced, two different transaminases are used for respectively constructing different chiral centers, the steps of protecting groups and deprotecting groups on the traditional route are not needed, the overall route is short, the used chemical reagents are few, the yield is high, and the method is suitable for industrial production. The industrial requirements of environmental protection and low cost are met.
Owner:杭州微远生物科技有限公司

Synthesis method of N-methylated polypeptide

The invention provides a method for synthesizing N-methylated polypeptide, which comprises the following steps: dissolving a carboxylic acid compound, N-methyl amino-acid ester hydrochloride or N-methyl amino-acid ester, an alkaline substance and pivaloic anhydride in an organic solvent, reacting at 15-80 DEG C for 3-10 hours, and post-treating the obtained reaction liquid to obtain an N-methyl dipeptide compound, the method comprises the following steps: removing a protecting group in an N-methyl dipeptide compound to obtain a free-state N-methyl dipeptide compound, and condensing the free-state N-methyl dipeptide compound and amino acid or N-methyl amino-acid ester protected by amino to obtain the N-methylated polypeptide, the mixed anhydride intermediate is formed in situ, and the reaction is completed in one step; according to the method, trimethylacetic anhydride is used as a condensing agent, the structure is simple, the reaction is safe, cheap and non-toxic, a large amount of nitrogen-containing byproducts are not generated in the reaction, and purification is convenient; the method is high in stereoselectivity, and racemization is avoided; according to the method, environment-friendly solvents such as ethyl acetate can be used, the reaction condition is mild, and the reaction time is short.
Owner:ZHEJIANG UNIV OF TECH

N-alkylated / sulfonated benzimidazole polyaryletherketone / sulphone with controllable grafting density as well as preparation method and application of N-alkylated / sulfonated benzimidazole polyaryletherketone / sulphone

The invention discloses N-alkylated / sulfonated benzimidazole polyaryletherketone / polyaryletherketone sulfone with controllable grafting density as well as a preparation method and application of the N-alkylated / sulfonated benzimidazole polyaryletherketone / polyaryletherketone sulfone. The preparation method comprises the following steps: firstly, introducing a protecting group on a phenolic hydroxyl group of a bisphenol monomer containing a benzimidazole structure, then carrying out nucleophilic substitution reaction on alkyl halide / alkyl halide sulfonic acid and-NH, and then removing the protecting group to obtain an N-alkylated / sulfonated benzimidazole functionalized bisphenol monomer; copolymerizing the monomer, a bisphenol monomer and a difluoro monomer to obtain a polymer; alkyl or alkyl sulfonic acid is introduced to a benzimidazole ring, so that-NH bonds are passivated, a steric hindrance effect is formed, and gelation of the polymer under a high polymerization degree is avoided; by adjusting the molar ratio of the monomers, the retention stability of the functional groups can be effectively controlled, and compared with the traditional grafting on the polymer, the non-regulation of functionalization and the gelation of the polymer are effectively avoided.
Owner:ZHEJIANG UNIV OF TECH

A method of synthesizing 4,4',4"-triaminotriphenylmethane

The application provides a method for synthesizing triaminotriphenylmethane, which does not need to use a solvent, uses N,N'-dibenzylaniline and trialkoxymethane as synthetic raw materials, and makes N,N'-dibenzylaniline and trialkoxymethane undergo a Friedel-Crafts alkylation reaction, so as to avoid the generation of 2,4',4"-triaminotriphenylmethane isomers in a traditional synthesis method by using the steric effect of two benzyl protective groups, thereby obtaining 4,4',4"-tri(N,N'-dibenzylaminophenyl)methane with high selectivity. 4,4',4"-tri(N,N'-dibenzylaminophenyl)methane is further subjected to a debenzylation reaction under neutral conditions to form triaminotriphenylmethane. According to the chemical structural formula of the target product, the benzyl group as the protective group of the amino group is reduced under a neutral environment, and the benzyl group is removed, and the formed byproduct is only toluene, which not only ensures the high yield and high selectivity of the target product, but also is very beneficial to obtaining high-purity 4,4',4"-triaminotriphenylmethane, and conforms to the principle of green chemistry.
Owner:BEIJING INST OF TECH

A method for synthesizing an antifreeze glycopeptide polypeptide

The application relates to a synthesis method of an anti-freezing glycopeptide polypeptide and belongs to the technical field of polypeptide drug synthesis. The method comprises the following steps: 2-CL-Resin is used as a carrier resin, under the condition of adding an activating agent, the carrier resin and alanine are coupled to obtain Fmoc-Ala-2-CL-Resin; according to the amino acid sequence of the anti-freezing glycopeptide, other amino acids are sequentially coupled through a solid-phase synthesis method; after a protecting group is removed and the carrier resin is cleaved, the anti-freezing glycopeptide crude peptide is obtained; and after purification, salt conversion and freeze-drying, the anti-freezing glycopeptide polypeptide is obtained. The method has the advantages of short synthesis period, low cost, easy post-treatment, few by-products, high product yield, facilitation of large-scale production of the anti-freezing glycopeptide, and considerable economic applicative value and wide application prospect.
Owner:ANHUI GUOPING PHARM CO LTD

Light-emitting device, light-emitting apparatus, display device, electronic device and lighting device

A light-emitting device comprising a light-emitting layer between a pair of electrodes, wherein the light-emitting layer contains a first material, a second material and a third material, wherein the first material can convert the triplet excitation energy into light emission and has a five-membered ring framework, wherein the first material is a metal complex, wherein the second material can convert the singlet excitation energy into light emission and has a luminophore and five or more protecting groups, wherein the luminophore is a condensed aromatic ring or a condensed heteroaromatic ring, wherein the five or more protecting groups each independently comprise an alkyl group having 1 to 10 carbon atoms, a substituted or unsubstituted cycloalkyl group having 3 to 10 carbon atoms or a trialkylsilyl group having 3 to 12 carbon atoms, wherein the third material comprises a diazine framework or a triazine framework, and wherein a T1 level of the first material is higher than an S1 level of the second material.
Owner:SEMICON ENERGY LAB CO LTD

Anti-epileptic polypeptide coupling medicine as well as preparation method and application thereof

PendingCN122031711ANervous disorderAerosol deliveryAntiepileptic drugPharmaceutical drug
The invention relates to an anti-epileptic polypeptide coupling medicine and a preparation method and application thereof, the polypeptide coupling medicine comprises an Fmoc protecting group, a permeation accelerating peptide and a cell penetrating peptide which are sequentially connected from the N end to the C end, and the permeation accelerating peptide is connected with an anti-epileptic medicine molecule. According to the invention, by fully utilizing the treatment requirements of epileptic seizure and the technical advantages of intranasal drug delivery, through the collaborative design of the protecting group, the functional polypeptide sequence and the anti-epileptic drug, the defects of poor brain targeting property, easy cyclization of a polypeptide carrier, low intranasal delivery efficiency and the like of the traditional anti-epileptic drug are overcome, non-invasive, efficient and low-toxicity epilepsy treatment is realized, and the application prospect is wide. And the preparation process is simplified, the clinical transformation requirement is met, and meanwhile, a new strategy is provided for non-invasive brain delivery of neuropeptide drugs.
Owner:THE NAT CENT FOR NANOSCI & TECH NCNST OF CHINA

CHEMICALLY ENCODED AND SPATIALLY LOCATED LIBRARIES SCREENING PLATFORMS

UndeterminedCY1126193T1Protecting groupLibrary
Encoded separation pool libraries are provided herein, which are useful, inter alia, in forming highly diverse and dense arrays for screening and detecting a variety of molecules. A method of immobilizing a microparticle on a solid support is disclosed, wherein the microparticle is covalently linked via first and second linkers to a linker domain (e.g., peptide, protein, small molecule) and a nucleic acid, and performing a decoding process on the nucleic acid domain, thereby determining the composition of the linker domain and its location on said solid support. The second linker is selectively cleavable provided that the first linker is not cleavable. The decoding may include hybridization or sequencing. The second linker is e.g. a photocleavable linker or includes -S(O)2NH- -NHS(O)2- -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-.The linker domain may be bound to a linker ligand (which may be fluorescent), unless protected by a protecting group, which may be removed.
Owner:CITY OF HOPE

Synthesis method of 5-nitro-2-aminophenol

The invention discloses a synthesis method of 5-nitro-2-aminophenol, which comprises the following steps: by using 2-chloro-4-nitroaniline as a raw material, providing an amino protecting group by using di-tert-butyl dicarbonate ester to obtain a compound 3; carrying out hydrolysis reaction in an alkaline environment to hydrolyze chlorine groups on benzene rings into hydroxyl groups to obtain a compound 4; and removing an amino protecting group under an acidic condition to obtain the 5-nitro-2-aminophenol. According to the method, 2-chloro-4-nitroaniline is used as a starting raw material, compared with expensive ortho-aminophenol, the cost of the raw material can be remarkably reduced, use of expensive catalysts in the hydrolysis process is avoided through amino protection, generation of the byproduct 2-amino-4-nitrophenol is effectively reduced, and the yield of the 2-chloro-4-nitrophenol is increased. And the synthesized 5-nitro-2-aminophenol has relatively high purity (99.5%) and relatively high yield (-86%). The method has the advantages of conventional production steps and conventional process equipment, and has a good application prospect.
Owner:JIUJIANG SHANSHUI TECH

A connector and its preparation method

ActiveCN115417907BPharmacophoreEngineering
This application discloses a linker and its preparation method. The linker includes pharmacophore P, pharmacophore Q, and deoxynucleotides and / or deoxynucleotide derivatives connecting pharmacophore P and pharmacophore Q. Pharmacophore P is obtained by removing the protecting group from group B, and pharmacophore Q is obtained by removing the protecting group from group X. Group B is obtained by chemically modifying the benzylquinolone carboxylic acid pharmacophore, and group X is obtained by chemically modifying the zenomeprazole pharmacophore. The linker is prepared by linking group B and group X with deoxynucleotides and / or deoxynucleotide derivatives to form the linker, including solid-phase synthesis technology. The method of this application can automatically synthesize molecular probes or bivalent drugs containing two pharmacophores, thereby replacing the traditional stepwise linking method, enabling efficient construction of screening libraries, and allowing control of the spatial distance and spatial orientation of the pharmacophores by adjusting the number and base arrangement of deoxynucleotides.
Owner:SHANGHAI JIAOTONG UNIV SCHOOL OF MEDICINE

Method for reducing dinitro group with high yield and retaining sensitive protecting group

The invention discloses a high-yield method for reducing dinitro and retaining sensitive protecting groups, which comprises the following steps: adding water, sodium dithionite and sodium carbonate into a container, stirring and clarifying, and dropwise adding a mixed solution containing raw materials; after the reaction is finished, extracting, separating liquid, concentrating, and purifying by silica gel column chromatography to obtain a product and a byproduct; the raw material is a compound containing a carbon-carbon double bond, a p-methoxybenzyl protecting group, a t-butyloxycarboryl protecting group and dinitro. Adding a byproduct into a phosphoric acid mixed solution for reaction; and after the reaction is finished, adding dichloromethane and water, dropwise adding triethylamine to adjust the pH value, extracting, separating liquid, drying, concentrating, and purifying by silica gel column chromatography to obtain the product. According to the method, a sodium hydrosulfite / sodium carbonate system and phosphoric acid step-by-step treatment strategy is adopted, reduction of dinitro is achieved under mild conditions, meanwhile, PMB protecting groups, Boc protecting groups and C-C double bonds are reserved, and the problem that stability and high yield of the protecting groups cannot be considered at the same time in an existing method is solved.
Owner:KANG YU LIFE SCI TECH (SUZHOU) CO LTD

Histidine-based unnatural amino acid, its production and use

Described is a compound for substituting amino acids of proteins or peptides, wherein the compound has the formula (1)wherein the stereocenter C1* represents CH that either results in the D- or L-form of the compound of formula (1); A− is a negatively charged ion compensating the positive charge; X1 is H or an amine protecting group; X2 is OH, an ester residue or an amide residue or an activated carboxylic acid derivate to be used for the formation of an amide bond; Y1, Y2 and Y3 are independently from each other a C1-C6 alkyl, and Z1 and Z2 are independently from each other a nucleobase, a C1 to C16 alkyl group, an aromatic residue or a heteroaromatic residue, wherein the aromatic residue or the heteroaromatic residue contains one 5, 6, or 7-membered ring or two condensed 5, 6, or 7-membered rings sharing two carbon atoms, wherein the aromatic residue or the heteroaromatic residue can be substituted by a linear or branched C1 to C16 alkyl group and / or a further aromatic group. Furthermore, a method for preparing this compound and proteins and peptides containing this compound are disclosed.
Owner:PHILIPPS UNIV MARBURG

Synthesis method of upatinib and intermediate Up-3 thereof

The invention belongs to the technical field of medicine synthesis, and particularly relates to a synthesis method of upatinib and an intermediate Up-3 thereof. The preparation method comprises the following steps: dissolving a compound Up-1 and a compound Up-2 in a solvent A, adding alkali 1, and reacting to obtain an intermediate Up-3; dissolving the intermediate Up-3 in a solvent B, adding an acid a, removing Boc protection and closing a ring to obtain an intermediate Up-6, and reacting under the action of an acid b to obtain a compound Up-14; the preparation method comprises the following steps: dissolving carbonyl diimidazole, trifluoroethylamine hydrochloride and alkali 2 in a solvent C, stirring, mixing with a compound Up-14 solution, reacting to obtain a compound Up-13, adding an alkali 3 solution, and removing Tos protecting groups to obtain upatinib. According to the method disclosed by the invention, the upatinib crude product is simply synthesized by taking Up-3 as a starting material through a two-pot method for the first time, the time of the whole process is saved, the total yield is relatively high, the purity of the obtained product is also relatively high, and the method is suitable for large-scale production.
Owner:CHANGZHOU YABANG PHARMA

Synthesis method of caffeoyl tripeptide-1

The invention belongs to the technical field of organic synthesis and cosmetics, and particularly relates to a synthesis method of caffeoyl tripeptide-1. According to the invention, caffeic acid and tripeptide-1 are used as raw materials, and a condensation reaction is carried out under mild conditions through a specific activation strategy and a protective group technology to generate a target product. The method has the advantages of simple steps, mild reaction conditions, high total yield, good product purity and the like.
Owner:SHANGHAI CORDAY BIOTECH CO LTD +1

Trirasilil hydrochloride intermediate and preparation method of trirasilil hydrochloride

According to the preparation method of the trirasilil hydrochloride disclosed by the technical scheme, the inventor introduces a specific amino protecting group to the intermediate of the trirasilil hydrochloride, so that the generation of byproducts in the reaction process is reduced. According to the technical scheme, the intermediate compound of the trilacilil hydrochloride is stable in property, not easy to degrade in the reaction process, capable of completely participating in the reaction and high in reaction yield, the usage amount of reaction raw materials is reduced, and the production cost of a final product is reduced. And the trirasilil hydrochloride is formed while the protecting group is removed, so that the preparation process is optimized. In the technical scheme, the initial reaction raw materials and the catalyst used in the reaction process are cheap and easy to obtain, so that the production cost of the product is further reduced. According to the technical scheme, the whole preparation process is mild in reaction condition and easy to operate, and the industrial amplification production cost is lower.
Owner:SHANDONG BESTCOMM PHARMA CO LTD +1

Process for the preparation of alpha-pyrone-polyketides

The application relates to the technical field of synthetic chemistry, and provides a preparation method of alpha-pyrone-polyketone, which comprises the following steps: coupling reaction of compound 3 and compound 2 to obtain compound 26; secondary alcohol group of the compound 26 is removed to obtain compound 27; the compound 27 is removed from a protection group to obtain the alpha-pyrone-polyketone shown in compound 1; wherein the structural formula of the compound is as follows: the preparation method of the alpha-pyrone-polyketone provided in the application is based on the instability of the bis-bisolefin, and is constructed by using an alkenyl tin intermediate and an alkenyl iodine intermediate through a coupling reaction, so that the operation is simple, the yield of each step is high, and the method can be widely popularized and applied.
Owner:SHENZHEN QIANYAN PHARM R & D TECH CO LTD

Methods and compositions for the enzyme-catalyzed synthesis of nucleosides containing protecting groups

ActiveJP2025536469AFermentationGenetic engineeringPyrimidine-nucleoside phosphorylaseNucleoside phosphorylase
The present invention provides a method and composition for the enzyme-catalyzed synthesis of nucleosides containing protecting groups. The method includes using pyrimidine nucleoside phosphorylase or uridine phosphorylase and purine nucleoside phosphorylase to catalyze the synthesis of nucleosides containing protecting groups from a substrate, the substrate including a substrate nucleoside, a substrate base, and a substrate phosphate, the substrate base containing a protecting group, the pyrimidine nucleoside phosphorylase including proteins having 80% or more identity to proteins P and NP shown in SEQ ID NO: 1, the uridine phosphorylase including proteins having 80% or more identity to protein UP shown in SEQ ID NO: 2, and the purine nucleoside phosphorylase including proteins having 80% or more identity to protein PNP shown in SEQ ID NO: 3, 7, or 8. This method solves the problem in the prior art that there is no biosynthetic method for producing nucleosides containing protecting groups, and is suitable for the field of enzyme catalysis.
Owner:ASYMCHEM LIFE SCI TIANJIN

Method for solid phase synthesis of leu-enkephalin by Fmoc method

The present application relates to a method for synthesizing leu-enkephalin by Fmoc method, which uses Fmoc-protected amino acid as monomer, and sequentially connects amino acid to resin. In the synthesis of leu-enkephalin, all the amino acids do not have any side chain protection group. The Fmoc protection group is removed by using a solution of 1.00 mol / L imidazole and 0.02 mol / L tricyclohexylphosphine in tetrahydrofuran, and finally leu-enkephalin is obtained by removing the resin with aqueous trifluoroacetic acid. The present application first uses imidazole and tricyclohexylphosphine as components of Fmoc deprotection agent, instead of traditional pyridine. The deprotection agent is not controlled by "controlled chemicals", is cheap and easy to obtain, is stable in nature, and is low in toxicity, volatility and corrosion. The deprotection agent has excellent Fmoc removal ability, does not cause phenolic ring acylation side reaction of tyrosine side chain, does not need any side chain protection, simplifies the production process of polypeptide, reduces the preparation cost of polypeptide, and provides great improvement space for the design of synthesis strategy of polypeptide containing basic sensitive side chain protection group.
Owner:YANTAI UNIV

A process for the preparation of baricitinib

ActiveCN117720543BPtru catalystBoronic acid
The application discloses a preparation method of baricitinib, and belongs to the technical field of drug synthesis. The method comprises the following steps: firstly, 2-[1-(ethylsulfonyl)-3-azetidinyl]acetonitrile and 4-pyrazole boron pinacol ester are subjected to a Michael addition reaction to obtain 1-(ethylsulfonyl)-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]-3-azetidine acetonitrile as an intermediate I; secondly, a protection group is introduced on the amino group of 4-chloropyrrolopyrimidine to obtain an intermediate II; finally, the intermediate I and the intermediate II are subjected to a Suzuki coupling process by adopting a method of combining a nickel pre-catalyst with a supporting ligand to obtain the baricitinib. The preparation method creatively realizes cross coupling of the baricitinib by adopting the cheap metal nickel as a catalyst, avoids the use of a heavy metal palladium catalyst, and has the advantages of low cost, low toxicity, small pollution, green environmental protection and the like.
Owner:NORTHEAST FORESTRY UNIV

Improved synthesis of radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18f]dcfpyl

To provide a method of synthesizing 2-(3{1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid ([18F]DCFPyL), which is a radiotracer for prostate-specific membrane antigen (PSMA) PET imaging for prostate cancer.SOLUTION: A synthesis method comprises the following steps: (i) radiofluorinating a DCFPyL precursor comprising ester moiety-protecting groups to form a radiofluorinated DCPFPyL precursor; (ii) deprotecting the ester moiety-protecting groups of the radiofluorinated DCPFPyL precursor of the step (i) with phosphoric acid to form [18F]DCFPyL in a reaction mixture; and (iii) purifying the [18F]DCFPyL from the reaction mixture of the step (ii) to provide [18F]DCFPyL.SELECTED DRAWING: Figure 5
Owner:JOHNS HOPKINS UNIVERSITY